Hartwig Medical Foundation expanded its partnership with Ultima Genomics by adopting the Ultima UG200 sequencing platform to scale whole-genome-informed ctDNA monitoring. The partners said the goal is to increase throughput while reducing the overall cost of cancer research and testing. Their focus includes further validation and implementation of Ultima’s paired plus minus sequencing (ppmSeq) technology to support longitudinal MRD and minimal residual disease monitoring workflows. They also plan to build end-to-end workflows so clinical genomics teams can implement Ultima data analysis in-house. The update comes as the broader field continues to shift toward more quantitative liquid biopsy strategies that can support repeated sampling across treatment timelines, not just single time-point assays.